Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
2027. jún. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
DK222 Study at Hopkins
2027. jan. 31.· PHASE1 · RECRUITING· CTGOV
Vizsgálat
Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC
2027. jan. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Retroviral Transduction of Human T Cells with a Chimeric Antigen Receptor Targeting PD-1 Ligands for Melanoma Immunotherapy.
2027. jan. 1.· Methods in molecular biology (Clifton, N.J.)· PUBMED
Vizsgálat
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
2026. dec. 4.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
2026. dec. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
2026. nov. 30.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung Cancer
2026. nov. 30.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
2026. nov. 30.· PHASE1_PHASE2 · RECRUITING· CTGOV
Vizsgálat
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
2026. nov. 30.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
2026. nov. 11.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
2026. nov. 11.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
CD27 and PD-1 expression patterns and exploratory ratio-based immunophenotypic indices in people living with HIV.
2026. nov. 6.· Cytometry. Part B, Clinical cytometry· PUBMED
Publikáció
PD-1/PD-L1 inhibitors plus chemotherapy in cervical cancer: A systematic review and meta-analysis.
2026. nov. 5.· Turkish journal of obstetrics and gynecology· PUBMED
Publikáció
Effective anti-PD-1 therapy reduces neutrophil infiltration via T cell-macrophage chemokine axis in hepatocellular carcinoma.
2026. nov. 4.· Cancer biology & medicine· PUBMED
Publikáció
Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy.
2026. nov. 4.· Journal for immunotherapy of cancer· PUBMED
Publikáció
Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial.
2026. nov. 4.· Cancer letters· PUBMED
Publikáció
Targeting CLDN3 Enhances PD-1 Blockade Efficacy in Gastric Cancer by Disrupting the NF-κB/p65-CXCL1-PD-L1 Immune Evasion Axis.
2026. nov. 4.· The Journal of biological chemistry· PUBMED
Publikáció
Mathematical and Mouse Models Identify Regulatory T-cell Influx as a Key Determinant of Acquired Resistance to PD-1 Immunotherapy.
2026. nov. 3.· Cancer research· PUBMED
Publikáció
Enhanced Antitumor Efficacy of Combined PTC596 and PD-1 Blockade in Hepatocellular Carcinoma.
2026. nov. 3.· Molecular cancer therapeutics· PUBMED
Publikáció
Targeting N-acetyltransferase 10 reprograms Treg function to enhance anti-PD-1 immunotherapy sensitivity in murine lung tumors.
2026. nov. 2.· The Journal of clinical investigation· PUBMED
Publikáció
Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
[68Ga]Ga-NODAGA-SNA006 PET/CT Reveals CD8+ T-Cell Dynamics in Lung Cancer Progression and Anti-PD-1 Response.
2026. nov. 2.· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publikáció
Baseline Circulating and Tumor γδ T Cells and Early Circulating CD8+PD-1+ Expansion Predict Response to Atezolizumab-Bevacizumab in HCC.
2026. nov. 2.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Vizsgálat
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV